ERYTECH Pharma S.A. (ERYP.PA)
ERYTECH Pharma S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, FR. The stock last traded at $0.80, up 0.25% on the session, giving a market capitalisation of $48.7M. Its beta of 2.13 implies it has historically moved more than the broad market.
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.
ERYTECH Pharma S.A. is most often compared with the following Healthcare names: